It remains to be seen whether the SHP2 inhibitor can cooperate with other inhibitors to reduce the adaptive feedback that occurs through RTK signaling in response to inhibition of several major pathway nodes, such as with MAPK inhibition in KRAS mutant cancers. Here, PTPN11 is linked to cancer.